文献速递淋巴瘤造血干细胞移植与细胞治疗

SARS-CoV-2疫苗接种及单克隆抗体对CD19靶向CAR-T细胞治疗后结局的影响:EPICOVIDEHA调查

Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey.
PubMed 文献 · Blood Adv · 2023-01-01

这项多中心回顾性研究基于EPICOVIDEHA调查数据,纳入64例既往接受CD19靶向CAR-T细胞治疗后感染COVID-19的患者。COVID-19相关总死亡率为31%,奥密克戎变异株感染者的死亡风险显著低于既往变异株(7% vs 58%,P=.012),仅单克隆抗体治疗似乎有效降低死亡率(从32%降至0%,P=.036)。

要点

  • CD19靶向CAR-T治疗后COVID-19相关总死亡率为31%。
  • 奥密克戎变异株感染死亡风险显著低于既往变异株(7% vs 58%,P=.012)。
  • 仅单克隆抗体治疗似乎有效降低死亡率(从32%降至0%,P=.036)。

核心结论

  • CAR-T细胞接受者感染COVID-19后的生存率随时间改善,既往疫苗接种联合单克隆抗体治疗显著降低其死亡风险。

研究设计与样本

  • 多中心回顾性研究,数据来自EPICOVIDEHA调查,共识别64例既往接受CD19靶向CAR-T细胞治疗后感染COVID-19的患者。
  • 试验注册号为NCT04733729。

主要发现

  • COVID-19所致总死亡率为31%。
  • 奥密克戎变异株感染者死于COVID-19的风险显著低于既往变异株感染者(7% vs 58%,P=.012)。
  • 诊断时已接种疫苗者26例,接种两剂疫苗显示COVID-19所致死亡风险有下降但未达统计学显著(33.3% vs 14.2%,P=.379)。
  • 病程似乎更轻,ICU入住更少(39% vs 14%,P=.054),住院时间更短(7天 vs 27.5天,P=.022)。
  • 在可选治疗方案中,仅单克隆抗体似乎有效降低死亡率(从32%降至0%,P=.036)。

关键数值与推荐

  • 奥密克戎变异株感染者死于COVID-19的风险为7%,既往变异株感染者为58%(P=.012)。
  • 接种两剂疫苗者COVID-19所致死亡风险为14.2%,未接种/未完成两剂者为33.3%(P=.379,未达统计学显著)。
  • 单克隆抗体治疗者死亡率为0%,未接受单克隆抗体治疗者为32%(P=.036)。

临床怎么用

  • 作者结论认为CAR-T细胞接受者感染COVID-19后的生存率随时间改善,既往疫苗接种联合单克隆抗体治疗显著降低死亡风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with previous CD19-directed chimeric antigen receptor (CAR) T-cell therapy have a prolonged vulnerability to viral infections. Coronavirus disease 2019 (COVID-19) has a great impact and has previously been shown to cause high mortality in this population. Until now, real-world data on the impact of vaccination and treatment on patients with COVID-19 after CD19-directed CAR T-cell therapy are lacking. Therefore, this multicenter, retrospective study was conducted with data from the EPICOVIDEHA survey. Sixty-four patients were identified. The overall mortality caused by COVID-19 was 31%. Patients infected with the Omicron variant had a significantly lower risk of death due to COVID-19 compared with patients infected with previous variants (7% vs 58% [P = .012]). Twenty-six patients were vaccinated at the time of the COVID-19 diagnosis. Two vaccinations showed a marked but unsignificant reduction in the risk of COVID-19-caused mortality (33.3% vs 14.2% [P = .379]). In addition, the course of the disease appears milder with less frequent intensive care unit admissions (39% vs 14% [P = .054]) and a shorter duration of hospitalization (7 vs 27.5 days [P = .022]). Of the available treatment options, only monoclonal antibodies seemed to be effective at reducing mortality from 32% to 0% (P = .036). We conclude that survival rates of CAR T-cell recipients with COVID-19 improved over time and that the combination of prior vaccination and monoclonal antibody treatment significantly reduces their risk of death. This trial was registered at www.clinicaltrials.gov as #NCT04733729.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. van Doesum JA, Salmanton-García J, Marchesi F, et al. Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOVIDEHA survey. Blood Adv. 2023. PMID: 37058479. doi:10.1182/bloodadvances.2022009578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。